SINGAPORE, March 12, 2026
Emerald Clinical Trials, a leading global clinical research organization (CRO), has been honored with the Best Clinical Trials Supplier Award for Outstanding Patient Recruitment & Engagement at the 2026 Asia Pacific Biopharma Excellence Awards (ABEA). The recognition highlights the company’s achievements in delivering patient-centric clinical trial strategies and operational excellence across the Asia-Pacific region, helping accelerate the development of innovative medicines and biologics.
The prestigious award underscores Emerald Clinical Trials’ ability to navigate complex patient recruitment landscapes in diverse healthcare systems, ensuring that clinical trials reach eligible participants efficiently while maintaining high ethical and operational standards. By enabling faster recruitment and stronger patient engagement, the organization plays a crucial role in helping pharmaceutical and biotechnology companies advance life-saving therapies from early development to regulatory approval and global patient access.
Excellence in Patient Recruitment and Engagement
The Asia Pacific Biopharma Excellence Awards recognize organizations that demonstrate leadership in advancing the biopharmaceutical research ecosystem, including innovations in clinical development, manufacturing, and regulatory science. Emerald Clinical Trials received the award for its exceptional expertise in patient recruitment strategies and engagement programs, which are essential for ensuring that clinical trials progress efficiently while maintaining patient trust and participation.
Recruiting suitable participants remains one of the most challenging aspects of clinical research, particularly in regions with diverse regulatory environments and healthcare infrastructures. Emerald Clinical Trials has developed specialized approaches to address these challenges by combining data-driven recruitment strategies, regional clinical networks, and patient-focused engagement initiatives.
Advertisement
These programs help ensure that trials enroll the right participants quickly while maintaining high levels of retention and compliance throughout the study process. The award reflects the company’s commitment to bridging the gap between innovative medical research and patient access to experimental therapies, enabling pharmaceutical sponsors to move clinical programs forward more effectively.
Strengthening the Asia-Pacific Clinical Research Ecosystem
The recognition also highlights Emerald Clinical Trials’ growing role in supporting biopharmaceutical innovation across the Asia-Pacific region, one of the fastest-growing markets for clinical research worldwide. The company works closely with pharmaceutical companies, biotechnology innovators, and healthcare institutions to deliver end-to-end clinical development solutions ranging from Phase I through Phase IV trials and real-world evidence studies. Its operational infrastructure allows sponsors to conduct complex clinical trials across multiple countries while maintaining regulatory compliance and high data quality standards.
The award ceremony took place on March 11, 2026, at the Sands Expo & Convention Centre in Singapore, where Emerald Clinical Trials was recognized alongside several leading life-science organizations for their contributions to the advancement of biologics and pharmaceutical products. Industry observers note that patient recruitment and engagement have become increasingly critical in modern clinical development, particularly as trials become more complex and involve precision medicine, rare disease therapies, and advanced biologic treatments.
Global CRO Expertise Supporting Drug Development
Emerald Clinical Trials brings more than 25 years of experience in global clinical research, providing specialized services that support pharmaceutical and biotechnology companies at every stage of clinical development. Headquartered in Singapore, the organization employs more than 800 professionals worldwide and collaborates with over 160 biotechnology companies and 15 of the world’s top 20 pharmaceutical firms.
Through its integrated global network of investigators, hospitals, and research institutions, Emerald Clinical Trials helps sponsors accelerate clinical trial timelines, ensure regulatory compliance, and maintain the highest standards of patient safety and data integrity. The company has also established strong expertise in renal research and other specialized therapeutic areas, enabling sponsors to conduct complex studies that require deep clinical and scientific knowledge. By combining global reach with local expertise, Emerald Clinical Trials continues to strengthen its role as a trusted partner in the development of next-generation medicines and therapies.
The recognition from the Asia Pacific Biopharma Excellence Awards further reinforces the company’s reputation as a leader in patient-centric clinical research and operational excellence in the global biopharmaceutical industry.
Source: Emerald Clinical Trials press release
